cotadutide
Peptideexperimental
Clinical trial activity
24 trials · 8 clinical orgs · 0 marketing orgs
Phase 1
13
Phase 2
11
Phase 3
1
Phase 4
0
Earliest trial started Feb 1, 2015 (NCT02394314)
Timeline
Indications
Mechanism of action
- Glucagon receptorACTIVATOR
GCGR activator
- GlucagonAGONIST
GCG agonist
Glucagon-like peptide 1 receptor agonist
- Glucagon receptorAGONIST
Glucagon receptor agonist
Chemistry & pharmacology
Loading structure…
SMILES
CCCCCCCCCCCCCCCC(=O)N[C@@H](CCC(=O)NCCCC[C@H](NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)Cc1c[nH]cn1)[C@@H](C)O)[C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@H](C(=O)N[C@@H](C)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](C)C(=O)NCC(=O)NCC(=O)O)C(C)C)C(=O)O- Mol. weight
- 3728.09 g/mol
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL4297630 ↗
Also known as
- medi0382
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05668936 | Phase 1 | Jan 10, 2023 | AstraZeneca |
| NCT05517226 | Phase 1 | Sep 6, 2022 | AstraZeneca, Parexel |
| NCT05364931 | Phase 2/Phase 3 (Phase 3) | Jul 14, 2022 | AstraZeneca |
| NCT05294458 | Phase 1 | Mar 28, 2022 | AstraZeneca, Quotient |
| NCT05437848 | Phase 1 | Feb 25, 2022 | AstraZeneca |
| NCT04515849 | Phase 2 | Aug 31, 2020 | AstraZeneca |
| NCT04208620 | Phase 1 | Jan 10, 2020 | AstraZeneca, MedImmune |
| NCT04019561 | Phase 2 | Sep 25, 2019 | MedImmune |
| NCT04091373 | Phase 1 | Sep 17, 2019 | MedImmune |
| NCT03745937 | Phase 2 | Jan 7, 2019 | MedImmune, Profil GmbH |
| NCT03596177 | Phase 2 | Sep 26, 2018 | MedImmune |
| NCT03625778 | Phase 1 | Aug 14, 2018 | MedImmune |
| NCT03645421 | Phase 2 | Aug 10, 2018 | AstraZeneca |
| NCT03550378 | Phase 2 | Jun 29, 2018 | MedImmune |
| NCT03555994 | Phase 2 | May 31, 2018 | Clinical Trial Consultants AB, Maastricht University, MedImmune |
| NCT03444584 | Phase 2 | May 8, 2018 | MedImmune |
| NCT03385369 | Phase 1 | Jan 5, 2018 | Anaheim Clinical Trials, MedImmune |
| NCT03341013 | Phase 1 | Nov 30, 2017 | MedImmune |
| NCT03347968 | Phase 1 | Nov 27, 2017 | MedImmune |
| NCT03235375 | Phase 1 | Oct 27, 2017 | MedImmune |
Showing 20 of 24 trials
Page 1 / 2
Organizations
Research & Development (8)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| MedImmune | For profit | 17 | 15 | 2 | 2015 |
| AstraZeneca | For profit | 9 | 9 | 3 | 2017 |
| Profil GmbH | For profit | 2 | 0 | 1 | 2017 |
| Anaheim Clinical Trials | For profit | 1 | 0 | 1 | 2018 |
| Clinical Trial Consultants AB | For profit | 1 | 0 | 1 | 2018 |
| Maastricht University | Academic/Hospital | 1 | 0 | 1 | 2018 |
| Parexel | For profit | 1 | 0 | 1 | 2022 |
| Quotient | For profit | 1 | 0 | 1 | 2022 |
8 organizations
Page 1 / 1